Acutaas Chemicals LimitedQuarter Ended September 30, 2026 Results & Financial Update
Acutaas Chemicals Limited: Quarter Ended September 30, 2026 consolidated results and company financials – revenue ₹4,369.64 Cr, PAT ₹12,314.25 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Acutaas Chemicals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Acutaas Chemicals Quarter Ended September 30, 2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Acutaas Chemicals reported strong top-line and bottom-line expansion for the second quarter of fiscal 2027, driven by sustained momentum in its pharmaceutical intermediates business.
Revenue from operations reached ₹4,369 million, representing a 42.7% increase compared to ₹3,062 million in the corresponding quarter of the previous fiscal year.
Profit after tax (PAT) for the quarter grew by 71.4% year-on-year to ₹1,231 million, compared to ₹719 million in Q2 FY26, supported by higher gross margins and operating leverage.
The pharmaceutical intermediates division delivered robust growth across both Contract Development and Manufacturing Operations (CDMO) and core advanced intermediate lines.
Conversely, the specialty chemicals segment experienced a softer performance due to a planned reduction in commodity chemical revenues alongside external headwinds.
Management noted that the U.S. specialty chemical business faced temporary disruption during the quarter resulting from a change in customer ownership.
Strong operating leverage and enhanced realization lifted EBITDA to ₹1,760 million, marking an 84.6% increase over the same period last year.
01 · Business model
What does Acutaas Chemicals do?
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a global manufacturer operating in advance pharmaceutical intermediates and specialty chemicals.
The company serves diverse customer segments across pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals, developing advanced pharmaceutical intermediates for regulated and generic APIs as well as New Chemical Entities (NCEs).
Its manufacturing operations are anchored by R&D-driven process chemistry, supplying customized advanced intermediates and specialty chemical formulations to domestic and international clients.
02 · Historical context
What shaped the business before this quarter
The company operated previously as Ami Organics Limited before transitioning to Acutaas Chemicals Limited, reflecting its expanding footprint in high-value electronic and specialty chemicals.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Quarter Ended September 30, 2026 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹4,369.64 Cr | ₹30,619.58 Cr | ₹329.67 Cr |
| Total income | ₹44,201.49 Cr | ₹31,603.31 Cr | ₹331.48 Cr |
| Profit before tax | ₹16,736.18 Cr | ₹9,617.98 Cr | ₹103.91 Cr |
| Profit after tax | ₹12,314.25 Cr | ₹7,185.59 Cr | ₹74.99 Cr |
| EPS | ₹15.29 | ₹8.82 | ₹9.04 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 281.8% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 383.0% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹39,831.85 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Growth was anchored by the advance intermediates business, encompassing both core products and CDMO operations, which expanded 53.1% year-on-year to ₹4,020 million in Q2 FY27.
Specialty chemicals revenue declined 20.0% year-on-year to ₹349 million during Q2 FY27, reflecting a deliberate phase-out strategy for select commodity lines and ownership changes at a major U.S. customer.
What drove margins
Gross margin for the quarter improved to 62.1%, expanding by 637 basis points year-on-year from 55.8% in Q2 FY26.
EBITDA margin climbed to 40.3% in Q2 FY27 compared to 31.1% in Q2 FY26, supported by favorable product mix and operating efficiencies across manufacturing units.
PAT margin reached 28.2%, up 472 basis points year-on-year from 23.5%, despite higher depreciation expenses and lower other income.
05 · Demand, customers & order book
Where demand is coming from
The company's Battery Chemicals and Fine Chemicals (BFC) business experienced headwinds during the quarter following a change in ownership at a key U.S. customer.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Generated ₹4,020 million in Q2 FY27 compared to ₹2,626 million in Q2 FY26, registering a 53.1% year-on-year increase.
Contributed ₹349 million in Q2 FY27 compared to ₹436 million in Q2 FY26, reflecting a 20.0% decline due to strategic phase-outs and customer ownership shifts.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Inaugurated a new manufacturing facility in South Korea ahead of schedule during the quarter, designed to produce high-purity chemicals for photoresists, semiconductor packaging, etching materials, and other electronic applications.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The early operationalization of the South Korea facility positions the company to tap into high-value electronic chemicals and semiconductor material markets.
09 · Reported developments
What changed operationally
Delivered Q2 FY27 revenue of ₹4,369 million (up 42.7% YoY) and PAT of ₹1,231 million (up 71.4% YoY).
10 · Pressure points & risks
What is not going smoothly
Specialty chemicals revenue decreased by 20.0% YoY due to strategic product phase-outs and disruption from a US customer ownership change.
11 · Management guidance & targets
What management is targeting from here
Management revised fiscal 2027 revenue growth guidance upward from 25% to around 30% based on improved revenue visibility and a robust order pipeline.
Management raised its EBITDA margin guidance for FY27 to a range of 38% to 40%.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
South Korea Facility Inauguration
The company completed the inauguration of its South Korea advanced chemical manufacturing plant ahead of schedule to serve semiconductor and electronic materials markets.
13 · Previous-quarter changes
What changed since the previous quarter
Revenue expanded sequentially from ₹3,297 million in Q1 FY27 to ₹4,369 million in Q2 FY27, representing a 32.5% increase.
14 · Key Q&A
The quarter, answered directly
What does Acutaas Chemicals do?
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a global manufacturer operating in advance pharmaceutical intermediates and specialty chemicals.
What is the clearest takeaway from Quarter Ended September 30, 2026?
Acutaas Chemicals reported strong top-line and bottom-line expansion for the second quarter of fiscal 2027, driven by sustained momentum in its pharmaceutical intermediates business.
What drove revenue or demand?
Growth was anchored by the advance intermediates business, encompassing both core products and CDMO operations, which expanded 53.1% year-on-year to ₹4,020 million in Q2 FY27.
What mattered most for margins or profitability?
Gross margin for the quarter improved to 62.1%, expanding by 637 basis points year-on-year from 55.8% in Q2 FY26.
What changed operationally beyond the headline numbers?
Inaugurated a new manufacturing facility in South Korea ahead of schedule during the quarter, designed to produce high-purity chemicals for photoresists, semiconductor packaging, etching materials, and other electronic applications.
What is management guiding or targeting from here?
Management revised fiscal 2027 revenue growth guidance upward from 25% to around 30% based on improved revenue visibility and a robust order pipeline.
15 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
16 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Ramp-up of South Korea Facility: Commercial execution and client qualification milestones for high-purity semiconductor chemicals at the newly inaugurated South Korean plant.
- 02
Specialty Chemicals Stabilization: Recovery trajectory of the specialty chemicals segment following customer ownership changes in the US market.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.